Adverse reactions and influencing factors in children with primary immunodeficiencies receiving intravenous immunglobulin replacement |
| |
| Affiliation: | 1. Department of Pediatrics, Dr. Behcet Uz Children’s Hospital, Izmir, Turkey;2. Department of Pediatric Immunology, Dr. Behcet Uz Children’s Hospital, Izmir, Turkey;1. Department of Epidemiology and Preventive Medicine, Ehime University Graduate School of Medicine, Ehime, Japan;2. Epidemiology and Medical Statistics Unit, Translational Research Center, Ehime University Hospital, Ehime, Japan;3. Wellness Research Fields, Faculty of Global and Regional Studies, University of the Ryukyus, Okinawa, Japan;1. Dresden International University, Division of Health Care Sciences, Center for Clinical Research and Management Education, Dresden, Germany;2. Hospital Medica Sur, Mexico City, Mexico;3. Laboratorio de Alergia Molecular, Mexico City, Mexico;4. Allergy and Immunology, Department of Pediatrics, New York University Langone Health, New York, NY, USA;5. Department of Pediatrics, Gastroenterology and Nutrition, Collegium Medicum, University of Warmia and Mazury, Olsztyn, Poland;6. Medica Sur Clinical Foundation and Hospital, Mexico City, Mexico;1. Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran;2. Department of Biology, Faculty of Basic Sciences, Maragheh University, Maragheh, Iran;3. Department of Veterinary Medicine, Shabestar Branch, Islamic Azad University, Shabestar, Iran;4. Department of Plant Protection, College of Agriculture, Ferdowsi University of Mashhad, Mashhad, Iran;5. Department of Immunology, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran;1. Clinical Pathology Department, Faculty of Medicine, Zagazig University, Zagazig City, Al Sharqia Governorate, Egypt;2. Department of Medical Microbiology & Immunology, Faculty of Medicine, Zagazig University, Zagazig City, Al Sharqia Governorate, Egypt;3. Department of Pediatrics, Faculty of Medicine, Zagazig University, Zagazig City, Al Sharqia Governorate, Egypt;1. Department of Allergy and Immunology, Ali Asghar children''s Hospital, Iran University of Medical Sciences, Tehran, Iran;2. Research Center of Pediatric Infectious Diseases, Institute of Immunology and Infectious Diseases, Iran University of Medical Sciences, Tehran, Iran;3. Department of Epidemiology, Faculty of Health, Iran University of Medical Sciences, Tehran, Iran;4. Research Center for Immunodeficiencies, Pediatrics Center of Excellence, Children''s Medical Center, Tehran University of Medical Science, Tehran, Iran;5. Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Educationan and Research Netwrork (USERN), Tehran, Iran |
| |
| Abstract: | ObjectivesWe aimed to determine adverse reactions and influencing factors, within the scope of the number of patients and total infusions, in patients with primary immunodeficiencies receiving intravenous immunoglobulin (IVIG) replacement.Materials and methodsChildren with primary immunodeficiencies receiving IVIG replacement in Izmir Dr Behcet Uz Children’s Hospital, between June 2014 and June 2016, were included in our study.ResultsThe total number of the patients receiving IVIG replacement was 145 (37 female, 108 male). The number of total IVIG infusions was 1214. Adverse reactions were observed in 44.8% of the patients and 14.2% of the infusions. Common variable immunodeficiency was the most common diagnosis of the patients and adverse reactions most commonly developed in this group (24.2%). In all infusions the most frequent adverse reaction was headache (7.8%); fever was the most frequent immediate side effect (3.9%), whereas headache was the most common delayed adverse effect (5.1%). By logistic regression analyses, history of adverse reaction to IVIG in previous infusions, existence of concomitant infectious disease, past or family history of atopic disease, to receive IVIG infusion at the first time, or being under 10 years old were found associated with adverse reactions. There was no correlation between the concentration of IVIG preparations and the rate of side-effect development.ConclusionsIn our study no severe adverse reaction to IVIG was observed, but many mild or moderate side effects occurred. Therefore, IVIG indications must be well identified. Patients, family of the patients and health care workers must be informed for adverse reactions. |
| |
| Keywords: | IVIG Primary immunodeficiency Adverse reactions |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
